EE04199B1 - Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine - Google Patents

Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine

Info

Publication number
EE04199B1
EE04199B1 EE9700344A EE9700344A EE04199B1 EE 04199 B1 EE04199 B1 EE 04199B1 EE 9700344 A EE9700344 A EE 9700344A EE 9700344 A EE9700344 A EE 9700344A EE 04199 B1 EE04199 B1 EE 04199B1
Authority
EE
Estonia
Prior art keywords
recombinant mva
vaccine
eukaryotic cell
mva virus
isolated eukaryotic
Prior art date
Application number
EE9700344A
Other languages
English (en)
Estonian (et)
Other versions
EE9700344A (et
Inventor
Sutter Gerd
Ohlmann Marion
Erfle Volker
Original Assignee
GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04199(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH filed Critical GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH
Publication of EE9700344A publication Critical patent/EE9700344A/xx
Publication of EE04199B1 publication Critical patent/EE04199B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EE9700344A 1995-07-04 1996-07-03 Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine EE04199B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK78295 1995-07-04
PCT/EP1996/002926 WO1997002355A1 (fr) 1995-07-04 1996-07-03 Virus mva recombinants et leur utilisation

Publications (2)

Publication Number Publication Date
EE9700344A EE9700344A (et) 1998-06-15
EE04199B1 true EE04199B1 (et) 2003-12-15

Family

ID=8097499

Family Applications (3)

Application Number Title Priority Date Filing Date
EE9700344A EE04199B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine
EEP200300331A EE05138B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
EEP200300332A EE04753B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin

Family Applications After (2)

Application Number Title Priority Date Filing Date
EEP200300331A EE05138B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
EEP200300332A EE04753B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin

Country Status (27)

Country Link
US (6) US6440422B1 (fr)
EP (3) EP1312678B1 (fr)
JP (3) JP4312260B2 (fr)
KR (1) KR19990028617A (fr)
CN (3) CN1554764B (fr)
AT (3) ATE239796T1 (fr)
AU (1) AU721735B2 (fr)
BR (1) BR9609303B8 (fr)
CA (3) CA2608864C (fr)
CZ (1) CZ292460B6 (fr)
DE (3) DE69635173T2 (fr)
DK (3) DK1312679T3 (fr)
EE (3) EE04199B1 (fr)
ES (3) ES2249647T3 (fr)
HK (2) HK1009830A1 (fr)
HU (2) HU224061B1 (fr)
IL (5) IL122120A (fr)
MX (1) MX9800025A (fr)
NO (1) NO322476B1 (fr)
NZ (1) NZ313597A (fr)
PL (1) PL186857B1 (fr)
PT (1) PT836648E (fr)
RU (1) RU2198217C2 (fr)
SI (3) SI1312679T1 (fr)
TW (2) TW575664B (fr)
UA (3) UA68327C2 (fr)
WO (1) WO1997002355A1 (fr)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7118754B1 (en) * 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
MY150893A (en) * 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
MY119381A (en) * 1996-12-24 2005-05-31 Gsf Forschungszentrum Umwelt Recombinant mva virus, and the use thereof
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
FR2784997A1 (fr) * 1998-10-22 2000-04-28 Transgene Sa Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
ATE412762T1 (de) * 1999-05-28 2008-11-15 Helmholtz Zentrum Muenchen Vektor zur integration von heterologen sequenzen in poxvirusgenomen
US20150231227A1 (en) * 2000-03-02 2015-08-20 Emory University Compositions and methods for generating an immune response
PL205922B1 (pl) 2000-03-14 2010-06-30 Bavarian Nordic As Zmodyfikowany wirus Ankara (MVA), zakażona nim komórka gospodarza, jego zastosowania, kompozycja farmaceutyczna i sposoby otrzymywania wirusa oraz sekwencji kwasu nukleinowego, peptydu i/lub polipeptydu
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
AU2002211654A1 (en) * 2000-10-10 2002-04-22 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
WO2002042480A2 (fr) 2000-11-23 2002-05-30 Bavarian Nordic A/S Variant du virus de la vaccine modified vaccinia ankara
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
DE10144664B4 (de) * 2001-09-11 2005-06-09 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
WO2003048184A2 (fr) 2001-12-04 2003-06-12 Bavarian Nordic A/S Vaccin a sous-unite de ns1 de flavivirus
CA2467099C (fr) * 2001-12-20 2013-01-29 Bavarian Nordic A/S Procede de recuperation et purification des poxvirus dans des cellules infectees
NZ547776A (en) * 2002-04-19 2009-08-28 Bavarian Nordic As Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein
NZ536500A (en) * 2002-05-16 2008-01-31 Bavarian Nordic As Expression of genes in modified vaccinia virus ankara by using the cowpox ATI promoter
DK1407033T3 (da) 2002-05-16 2006-05-22 Bavarian Nordic As Intergeniske områder som insertionssteder i genomet af Modified Vaccinia Virus Ankara (MVA)
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
PT1434858E (pt) 2002-09-05 2008-07-28 Bavarian Nordic As Método de amplificação de um poxvírus em condições sem soro
DE10249390A1 (de) * 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
EA012723B1 (ru) * 2002-11-25 2009-12-30 Бавариан Нордик А/С Рекомбинантный поксвирус, содержащий по меньшей мере два промотора ati вируса коровьей оспы, и его применение
ATE403005T1 (de) * 2003-02-18 2008-08-15 Helmholtz Zentrum Muenchen Rekombinantes mva und verfahren zur erzeugung davon
CA2515890C (fr) * 2003-02-20 2013-09-17 Therion Biologics Corporation Nouveaux sites d'insertion dans des vecteurs de variole
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
NZ542902A (en) 2003-03-27 2007-06-29 Ottawa Health Research Inst Mutant vesicular stomatitis viruses and use thereof
WO2004093905A1 (fr) * 2003-04-16 2004-11-04 City Of Hope Antigenes du cytomegalovirus humain exprimes dans vaccinia ankara modifie (mva), et methodes d'utilisation
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
EP1925626A1 (fr) 2003-07-21 2008-05-28 Transgene S.A. Nouvelles cytokines multifonctionnelles
WO2005017208A1 (fr) * 2003-07-31 2005-02-24 George Mason Intellectual Properties, Inc. Compositions et methodes de traitement et/ou de prevention d'une infection par le virus hiv
EP1518932A1 (fr) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Mutant du virus de la vaccine Ankara modifié (MVA) et utilisation correspondante
EP1536015B1 (fr) 2003-11-24 2007-10-31 Bavarian Nordic A/S Promoteurs pour expression dans le virus de la vaccine ankara modifié
JP4719855B2 (ja) 2003-12-05 2011-07-06 国立大学法人北海道大学 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
EP1683870A1 (fr) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccins à base de l'utilisation de MVA
WO2006113927A2 (fr) * 2005-04-20 2006-10-26 University Of Washington Peptides de la vaccine immunogenes et procedes d'utilisation de ces peptides
WO2007136763A2 (fr) * 2006-05-19 2007-11-29 Sanofi Pasteur, Inc. Composition immunologique
ES2671230T3 (es) * 2006-06-20 2018-06-05 Transgene Sa Procedimiento para producir poxvirus y composiciones de poxvirus
US7972605B2 (en) * 2006-09-08 2011-07-05 Duke University Modified vaccinia ankara virus vaccine
CN105769931B (zh) 2006-09-15 2021-04-27 渥太华医院研究机构 溶瘤弹状病毒
US7807146B2 (en) 2006-10-06 2010-10-05 Bn Immunotherapeutics, Inc. Methods for treating cancer with a recombinant MVA expressing HER-2
US20080241139A1 (en) * 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
WO2008094510A2 (fr) * 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Procédés de modulation de fonction immunitaire
DK2208737T3 (en) 2007-05-03 2017-09-18 Lysomab Gmbh Complement factor H-derived short-consensus repeat antibody constructs
AU2008250596C1 (en) * 2007-05-14 2010-11-25 Bavarian Nordic A/S Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines
US8003363B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
US20100285050A1 (en) * 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
BRPI0800485B8 (pt) * 2008-01-17 2021-05-25 Univ Minas Gerais vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
MX2010008970A (es) 2008-02-12 2011-05-30 Sanofi Pasteur Ltd Metodo que utiliza cromatografia de intercambio ionico y filtracion en gel para la purificacion de poxvirus.
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2760315C (fr) 2009-04-30 2019-05-28 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Vecteurs d'immunisation modifies
US9393299B2 (en) * 2009-08-07 2016-07-19 Transgene S.A. Composition for treating HBV infection
EP2501405A4 (fr) 2009-11-20 2013-12-04 Inviragen Inc Compositions, procédés et utilisations pour des éléments de poxvirus dans des constructions de vaccins
US9005632B2 (en) 2009-11-20 2015-04-14 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
WO2011119920A2 (fr) 2010-03-25 2011-09-29 Oregon Health & Science University Glycoprotéines du cmv et vecteurs recombinés
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
EP2668201A2 (fr) 2011-01-28 2013-12-04 Sanofi Pasteur SA Compositions immunogeniques comprenant des dérivés du polypeptide gp41 de hiv
WO2012151272A2 (fr) 2011-05-02 2012-11-08 Tremrx, Inc. Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
PL2739293T3 (pl) * 2011-08-05 2020-11-16 Sillajen Biotherapeutics, Inc. Sposoby i kompozycje wytwarzania wirusa krowianki
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2761011B1 (fr) * 2011-09-26 2018-05-23 Theravectys Utilisation de protéines gag hors sous-type gag b pour l'encapsidation de vecteurs lentiviraux
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2788021B1 (fr) 2011-12-09 2017-01-18 Bavarian Nordic A/S Vecteur du poxvirus codant des antigènes bactériens lié à le fragment c de la toxine tétanique
EP2620446A1 (fr) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogènes pour la vaccination contre le VIH
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2014009433A1 (fr) 2012-07-10 2014-01-16 Transgene Sa Facteur de ressuscitation de mycobactéries convenant comme adjuvant
BR112015000530A2 (pt) 2012-07-10 2018-08-28 Transgene Sa vacina de antígeno micobacteriano.
WO2014043535A1 (fr) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions destinées à traiter le cancer
CN109134640A (zh) 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
US20140286981A1 (en) 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
WO2015104380A1 (fr) 2014-01-09 2015-07-16 Transgene Sa Fusion d'antigènes mycobactériens hétérooligomères
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
PT3197489T (pt) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana
US11701418B2 (en) 2015-01-12 2023-07-18 Geovax, Inc. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
WO2016131945A1 (fr) 2015-02-20 2016-08-25 Transgene Sa Produit de combinaison modulateur de l'autophagie
EP3069730A3 (fr) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
HUE045993T2 (hu) 2015-12-15 2020-01-28 Janssen Vaccines & Prevention Bv Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások
JP7150611B2 (ja) 2016-01-08 2022-10-11 ジオバックス・インコーポレイテッド 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法
BR112018015696A2 (pt) 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
BR112018016948A2 (pt) * 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos
EP3452081A1 (fr) 2016-05-04 2019-03-13 Transgene SA Polythérapie avec un ligand de tlr9 cpg
US10273268B2 (en) 2016-06-16 2019-04-30 Janssen Vaccines & Prevention B.V. HIV vaccine formulation
EP3506937A1 (fr) 2016-09-02 2019-07-10 Janssen Vaccines & Prevention B.V. Procédés pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets subissant un traitement antirétroviral
SG10202001956UA (en) 2016-09-15 2020-04-29 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
JP7272965B2 (ja) 2017-06-15 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖ抗原をコードするポックスウイルスベクターおよびその使用方法
WO2018234506A2 (fr) 2017-06-21 2018-12-27 Transgene Sa Vaccin personnalisé
CA3069052A1 (fr) 2017-07-19 2019-01-24 Janssen Vaccines & Prevention B.V. Mutations de proteine d'enveloppe du vih stabilisant la forme trimere
WO2019018724A1 (fr) 2017-07-21 2019-01-24 Janssen Vaccines & Prevention B.V. Procédés d'induction sûre d'une immunité croisée multiclades contre une infection par le virus de l'immunodéficience humaine chez l'être humain
WO2019055888A1 (fr) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Méthodes pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets subissant un traitement antirétroviral
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
EP3973973A1 (fr) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Vecteur de plateforme oncolytique pour administration systémique
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
TW202110476A (zh) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
WO2021076998A1 (fr) * 2019-10-16 2021-04-22 KaliVir Immunotherapeutics LLC Virus producteurs pour la génération de rétrovirus in situ
WO2021094984A1 (fr) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Régimes posologiques pour vaccins
EP3842065A1 (fr) 2019-12-23 2021-06-30 Transgene Procédé de conception d'un poxvirus recombinant pour un vaccin thérapeutique
WO2021260065A1 (fr) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Vaccin à base de mva contre la covid-19 exprimant des antigènes de sras-cov-2
EP3928789A1 (fr) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Vaccin à base de mva contre le covid-19 exprimant les antigènes du sars-cov-2
CA3215344A1 (fr) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Virus oncolytiques d'expression de cmh modifiee
EP4108257A1 (fr) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Vaccin à base du virus de la vaccine ankara (mva) contre la covid-19 exprimant une protéine sars-cov-2 s stabilisée dans une préfusion
WO2022269003A1 (fr) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas Vaccin à base de mva exprimant une protéine s du sars-cov-2 stabilisée par préfusion
WO2023077147A2 (fr) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. Vaccins à lymphocytes t pour patients présentant une immunité humorale réduite
WO2023213763A1 (fr) 2022-05-02 2023-11-09 Transgene Poxvirus codant pour un agent de liaison comprenant un sdab anti-pd-l1
WO2023213764A1 (fr) 2022-05-02 2023-11-09 Transgene Polypeptide de fusion comprenant un anti-pd-l1 sdab et un membre du tnfsf
WO2023220283A1 (fr) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Adjuvant de poxvirus pour vaccination par lymphocytes t
EP4316514A1 (fr) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Vecteurs à base de mva et leur utilisation comme vaccin contre le sars-cov-2
WO2024193905A1 (fr) 2023-03-17 2024-09-26 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Formulation d'antigène du vhb pour traitement de l'hépatite b

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
WO1984002077A1 (fr) 1982-11-30 1984-06-07 Us Health Procede de production de recombinants du virus de la variole pour l'expression de genes etrangers
US5679511A (en) * 1986-10-06 1997-10-21 Donald Guthrie Foundation For Medical Research, Inc. CDNA clones for a regulatory protein in the melanin-production pathway
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
CN1042564A (zh) * 1988-11-11 1990-05-30 中国科学院上海生物化学研究所 乙肝疫苗的制备方法及其制品
JPH03271233A (ja) * 1990-03-19 1991-12-03 Inst Pasteur ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発
WO1993008836A1 (fr) 1991-10-28 1993-05-13 Institut Pasteur Induction de protection contre les infections virales par utilisation d'une synergie entre les proteines virales et les peptides viraux
WO1994014459A1 (fr) * 1992-12-22 1994-07-07 Ludwig Institute For Cancer Research Procedes de detection et de traitement de personnes presentant des cellules anormales exprimant les antigenes peptidiques hla-a2/tyrosinase
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
KR100235849B1 (ko) * 1993-10-19 1999-12-15 에가시라 구니오 HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
US5676950A (en) * 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals

Also Published As

Publication number Publication date
UA75410C2 (en) 2006-04-17
IL122120A (en) 2005-07-25
ATE304057T1 (de) 2005-09-15
EE9700344A (et) 1998-06-15
EP0836648B1 (fr) 2003-05-07
TW200305646A (en) 2003-11-01
DE69635172T2 (de) 2006-06-22
US20030035792A1 (en) 2003-02-20
US20100291139A1 (en) 2010-11-18
AU721735B2 (en) 2000-07-13
CN1782071A (zh) 2006-06-07
CZ424197A3 (cs) 1998-03-18
CA2608864A1 (fr) 1997-01-23
BR9609303A (pt) 1999-05-25
US20070071770A1 (en) 2007-03-29
ES2249647T3 (es) 2006-04-01
CA2608864C (fr) 2010-09-07
CN1554764B (zh) 2012-03-21
HUP9802217A3 (en) 1999-09-28
CN1554764A (zh) 2004-12-15
EP1312679B8 (fr) 2005-11-23
EE200300331A (et) 2003-10-15
ES2249648T3 (es) 2006-04-01
JP4764367B2 (ja) 2011-08-31
NZ313597A (en) 1999-01-28
EP0836648A1 (fr) 1998-04-22
HU224061B1 (hu) 2005-05-30
US8197825B2 (en) 2012-06-12
NO980026L (no) 1998-01-02
AU6611096A (en) 1997-02-05
EP1312678B1 (fr) 2005-09-07
BR9609303B1 (pt) 2014-04-08
EP1312679B1 (fr) 2005-09-07
DK1312678T3 (da) 2005-12-19
CA2225278C (fr) 2009-01-27
HK1068015A1 (en) 2005-04-22
CA2225278A1 (fr) 1997-01-23
EE04753B1 (et) 2006-12-15
DK1312679T3 (da) 2006-01-09
IL164318A0 (en) 2005-12-18
DE69635172D1 (de) 2005-10-13
SI0836648T1 (en) 2003-12-31
MX9800025A (es) 1998-03-31
TW575664B (en) 2004-02-11
HUP9802217A2 (hu) 1999-01-28
PL186857B1 (pl) 2004-03-31
CA2596274C (fr) 2010-09-07
PL324347A1 (en) 1998-05-25
UA68327C2 (en) 2004-08-16
HK1009830A1 (en) 1999-06-11
US8153138B2 (en) 2012-04-10
DE69628011D1 (de) 2003-06-12
HU0402350D0 (en) 2005-01-28
NO322476B1 (no) 2006-10-09
KR19990028617A (ko) 1999-04-15
JP2007252374A (ja) 2007-10-04
EE200300332A (et) 2003-10-15
WO1997002355A1 (fr) 1997-01-23
ES2199294T3 (es) 2004-02-16
CA2596274A1 (fr) 1997-01-23
ATE304058T1 (de) 2005-09-15
HU229261B1 (en) 2013-10-28
IL202448A0 (en) 2011-07-31
IL219528A0 (en) 2012-06-28
DE69635173D1 (de) 2005-10-13
US20070071769A1 (en) 2007-03-29
DE69628011T2 (de) 2004-03-18
EP1312678A1 (fr) 2003-05-21
SI1312679T1 (sl) 2006-02-28
ATE239796T1 (de) 2003-05-15
JPH11509091A (ja) 1999-08-17
US20100266630A1 (en) 2010-10-21
JP2007244382A (ja) 2007-09-27
IL122120A0 (en) 1998-04-05
NO980026D0 (no) 1998-01-02
RU2198217C2 (ru) 2003-02-10
UA75411C2 (en) 2006-04-17
PT836648E (pt) 2003-09-30
SI1312678T1 (sl) 2006-02-28
US7198934B2 (en) 2007-04-03
JP4764366B2 (ja) 2011-08-31
CN1154742C (zh) 2004-06-23
US6440422B1 (en) 2002-08-27
TWI245075B (en) 2005-12-11
IL212933A0 (en) 2011-07-31
IL164318A (en) 2013-08-29
BR9609303B8 (pt) 2014-05-06
EE05138B1 (et) 2009-02-16
JP4312260B2 (ja) 2009-08-12
DK0836648T3 (da) 2003-08-25
CN1189857A (zh) 1998-08-05
DE69635173T2 (de) 2006-07-13
EP1312679A1 (fr) 2003-05-21
CZ292460B6 (cs) 2003-09-17

Similar Documents

Publication Publication Date Title
EE04199B1 (et) Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine
ATE236262T1 (de) Rekombinanter schweinepocken-virus
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
HUP9802587A2 (hu) Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
MY134484A (en) Recombinant mva virus, and the use thereof
MY119381A (en) Recombinant mva virus, and the use thereof
MY157873A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231